Secukinumab: all 175 studies that test it

Page 2 of 2. Open to participants first (16), then studies with results posted, then the rest; newest registration first within each.

• A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) PatientsCompletedNCT01426789Phase 2Results posted
• Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type PsoriasisCompletedNCT01412944Phase 3Results posted
• Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose RegimensCompletedNCT01406938Phase 3Results posted
• Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA)CompletedNCT01392326Phase 3Results posted
• Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα AgentsCompletedNCT01377012Phase 3Results posted
• Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 YearCompletedNCT01365455Phase 3Results posted
• A 3-arm Proof of Concept Study of AIN457, ACZ885 or Corticosteroids in Patients With Polymyalgia RheumaticaTerminatedNCT01364389Phase 2Results posted
• Efficacy, Safety and Tolerability of Secukinumab in Patients With Rheumatoid Arthritis Taking MethotrexateCompletedNCT01359943Phase 2Results posted
• Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type PsoriasisCompletedNCT01358578Phase 3Results posted
• 16 Week Efficacy and 2 Year Long Term Safety and Efficacy of Secukinumab in Patients With Active Ankylosing SpondylitisCompletedNCT01358175Phase 3Results posted
• The Effects of a Single Intravenous Administration of Secukinumab (AIN457) or Canakinumab (ACZ885) in Dry Eye PatientsCompletedNCT01250171Phase 2Results posted
• AIN457 Regimen Finding Extension Study in Participants With Moderate to Severe PsoriasisCompletedNCT01132612Phase 2Results posted
• Safety and Tolerability of AIN457 in Adults (18-65 Years) With Moderate to Severe Ankylosing SpondylitisCompletedNCT01109940Phase 2Results posted
• Safety and Efficacy of AIN457 in Patients With Active Non-infectious UveitisTerminatedNCT01095250Phase 3Results posted
• 38 Week Extension Study to CAIN457C2303TerminatedNCT01093846Phase 3Results posted
• Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious UveitisTerminatedNCT01090310Phase 3Results posted
• A Dose Ranging Study of AIN457 in Patients With Moderate to Severe Chronic Plaque-type PsoriasisCompletedNCT01071252Phase 2Results posted
• POC-MD MRI-based Trial in Relapsing-remitting Multiple SclerCompletedNCT01051817Phase 2Results posted
• Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious UveitisTerminatedNCT01032915Phase 3Results posted
• An Open Label Safety and Tolerability Study of AIN457 in Patients With Moderate to Severe Crohn's DiseaseTerminatedNCT01009281Phase 2Results posted
• Phase III Study in Refractory Behcet's DiseaseCompletedNCT00995709Phase 3Results posted
• AIN457 Regimen Finding Study in Patients With Moderate to Severe PsoriasisCompletedNCT00941031Phase 2Results posted
• Efficacy, Safety and Tolerability of AIN457 in Patients With Rheumatoid Arthritis (RA) Taking Methotrexate (MTX)CompletedNCT00928512Phase 2Results posted
• Efficacy of AIN457 in Adults (18-65 Years) With Psoriatic ArthritisCompletedNCT00809614Phase 2Results posted
• Double Blind, Placebo Controlled Study to Assess Efficacy of AIN457 in Moderate to Severe Ankylosing SpondylitisCompletedNCT00809159Phase 2Results posted
• Multiple-loading Dose Regimen Study in Patients With Chronic Plaque-type PsoriasisCompletedNCT00805480Phase 2Results posted
• Phase II Efficacy Study Looking at a Single-dose of One of Three Dose Levels of AIN457 in Patients With Chronic Plaque-type PsoriasisCompletedNCT00770965Phase 2Results posted
• Safety and Efficacy of AIN457 in Noninfectious UveitisCompletedNCT00685399Phase 2Results posted
• Double Blind, Placebo-controlled, Study of the Safety, Tolerability and Pharmacokinetics of AIN457 in Rheumatoid Arthritis PatientsCompletedNCT00669942Phase 1/2Results posted
• A Study Comparing AIN457 to Placebo in Subjects With a Diagnosis of Moderate to Severe Stable Plaque PsoriasisCompletedNCT00669916Phase 1/2Results posted
• Efficacy, Safety and Tolerability of AIN457 in Moderate to Severe Active Crohn's DiseaseTerminatedNCT00584740Phase 2Results posted
• Pharmacokinetic, Safety and Immunogenicity Study of New Process CMAB015 and Cosentyx in Healthy VolunteersCompletedNCT07254325Phase 1
• Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)Active, not recruitingNCT06331312Phase 3
• Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMRCompletedNCT06130540Phase 1
• Outcome of Treatment With Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis at Tertiary Care Hospital.CompletedNCT05891964Phase 4
• Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR)CompletedNCT05767034Phase 3
• Pharmacokinetic, Safety and Immunogenicity Study of CMAB015 and Cosentyx in Healthy VolunteersCompletedNCT05734482Phase 1
• Secukinumab in Active Non-segmental VitiligoCompletedNCT05676333Phase 4
• A Study of Secukinumab to Evaluate Maintenance of Response in Participants With Non-radiographic Axial Spondyloarthritis Who Achieved RemissionActive, not recruitingNCT05622708Phase 4
• The Clinical Efficacy and the Changes of Immune Cells Subsets With Bioagents in Ankylosing Spondylitis PatientsActive, not recruitingNCT05527444Phase 4
• Efficacy and Safety of Secukinumab in Patients With New Onset of Giant Cell Arteritis Who Are in Clinical RemissionCompletedNCT05380453Phase 3
• Study to Demonstrate the Efficacy and Safety of Secukinumab up to 224 Weeks in Subjects With Active Peripheral Spondyloarthritis (pSpA).WithdrawnNCT05206591Phase 3
• COVID-19 VaccinE Response in Rheumatology PatientsCompletedNCT05080218Phase 4
• Scientific Substantiation and Assessment of the Effectiveness of Pathogenetic Methods of Therapy for Congenital Ichthyosis in ChildrenStatus unknownNCT04996485Phase 4
• An Efficacy Study of Secukinumab In Enthesitis of Psoriatic Arthritis PatientsStatus unknownNCT04967950Phase 1
• Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA)CompletedNCT04930094Phase 3
• EBIO - Enthesitis Biopsy StudyStatus unknownNCT04887597Phase 4
• A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 1CompletedNCT04589026Phase 1
• A Study to Evaluate the Efficacy and Safety of Secukinumab in Adult Patients With Skin Types IV-VI With Moderate to Severe Plaque PsoriasisCompletedNCT04571567Phase 4
• Open Label Study of the Effects of Secukinumab on Nail Psoriasis and Non-Invasive Measures of Enthesitis (Phase IV)CompletedNCT04535999Phase 4
• An Efficacy Study of Secukinumab in Plaque Psoriasis Patients With Subclinical Psoriatic Arthritis as Measured by Musculoskeletal UltrasoundWithdrawnNCT04488185Phase 4
• Methotrexate Versus Secukinumab Safety in Psoriasis Patients With Metabolic SyndromeStatus unknownNCT04469829Phase 4
• COLchicine Versus Ruxolitinib and Secukinumab in Open-label Prospective Randomized Trial in Patients With COVID-19CompletedNCT04403243Phase 2
• Dose Reduction of IL17 and IL23 Inhibitors in PsoriasisCompletedNCT04340076Phase 4
• A Trial of SHR-1210 in Combination With AIN457 in Patients With MSS CRC（SHR-1210-AIN457）Status unknownNCT04298320Phase 1/2
• Secukinumab for the Inflammatory Phase of Pyoderma GangrenosumWithdrawnNCT04274166Phase 2
• A Study to Assess the Safety and Efficacy of Secukinumab in Alleviating Symptoms of Discoid Lupus ErythematosusWithdrawnNCT03866317Phase 2
• Personalized Therapies in Inflammatory Complex DiseaseCompletedNCT03651518Phase 2
• Treat-to-target With Secukinumab in Axial SpondyloarthritisStatus unknownNCT03639740Phase 4
• PsA Secukinumab XCT Structural Progression StudyCompletedNCT03623867Phase 4
• Investigation of Efficacy of Secukinumab in Patients With Moderate to Serve Atopic DermatitisCompletedNCT03568136Phase 2
• Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial SpondyloarthritisCompletedNCT03445845Phase 4
• Mechanism of Action of Anti-IL17 Therapy in Peripheral SpondyloarthritisCompletedNCT03358134Phase 3
• Cosentyx (Secukinumab) for the Treatment of Adult Onset Pityriasis Rubra PilarisCompletedNCT03342573Phase 1
• Secukinumab Therapy for the Treatment of Moderate to Severe Plaque Psoriasis With Response Monitoring Using Optical Coherence Tomography (OCT).Status unknownNCT03307447Phase 4
• Exploratory Trial Evaluating Cosentyx (Secukinumab) for Patients With Moderate-to-Severe Hidradenitis SuppurativaCompletedNCT03099980Early Phase 1
• Effect of Secukinumab in the Treatment of Psoriatic ArthritisCompletedNCT02854163Phase 2
• Anti-IL-17 a New Treatment for Contact DermatititisStatus unknownNCT02778711Phase 3
• Single-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoderma GangrenosumCompletedNCT02733094Phase 1/2
• Investigate Effect of Secukinumab on the PK of Midazolam in Patients With Mod to Sev Plaque PsoriasisCompletedNCT02607774Phase 1
• Psoriasis-Arthritis & Bone ProgramCompletedNCT02483234Phase 2
• Distribution of Secukinumab (AIN457) Into Dermal Interstitial Fluid After a Single Subcutaneous Administration of 300 mgCompletedNCT01539213Phase 1
• Study to Evaluate the Long Term Use of Treatment With AIN457 for UveitisWithdrawnNCT01327664Phase 3
• Extension Study to Assess Safety and Efficacy of AIN457 in Patients With Active Non-infectious UveitisWithdrawnNCT01103024Phase 3
• Effect of AIN457 on Ozone-induced Airway Neutrophilia Compared to Placebo and Corticosteroid in Healthy SubjectsCompletedNCT00920933Phase 1/2

← Secukinumab overview